News & Press Releases

Mintz advised the placement agent in connection with SCYNEXIS’ up to $92.2 million private placement. The private placement included upfront gross proceeds of approximately $40.0 million in common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants, and up to an additional $52.2 million in gross proceeds if the common warrants are exercised for cash, subject to stockholder approval to increase the number of authorized shares of common stock.

Of Counsel Michelle Capezza was quoted in a Business Insider article examining the push to expand private credit and other alternative investments into 401(k) retirement plans. The article discusses these developments in light of new regulations proposed by the Department of Labor, as well as ongoing questions about liquidity, valuation, and market volatility within the private credit space.

Law360 recently highlighted commentary from ITC Practice Co-chair Robert Vlasis in an article examining the rise in Section 337 investigations involving patents and other IP being litigated at the US International Trade Commission for the first time. The piece outlines several developments that may be contributing to this trend, including the Federal Circuit’s Lashify decision and recent USPTO procedural changes affecting PTAB challenges.

Michael Arnold, Chair of Mintz’s Employment Practice, was featured on a recent episode of the Corner Office with Elise Powers podcast, where he spoke about leadership, wellbeing, and sustaining a long-term career in Big Law.

Mintz represented Synnovation Therapeutics LLC, a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology, in connection with its definitive agreement with Novartis to acquire Synnovation’s wholly-owned subsidiary, Pikavation Therapeutics Inc., and its portfolio of pan mutant selective PI3Kα inhibitor programs, including its lead clinical asset SNV4818.  

Mintz advised the underwriters in connection with SAB Biotherapeutics’ $85 million public offering.